REG - Scancell Holdings - Director/PDMR Shareholding

Scancell HoldingsAnnouncement

04/08/2025 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250804:nRSD8382Ta&default-theme=true

RNS Number : 8382T  Scancell Holdings Plc  04 August 2025

4 August 2025

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Director Dealing

 

Scancell Holdings plc (AIM: SCLP), the developer of Immunobody® and
Moditope® active immunotherapies to treat cancer, announces that Vulpes
Testudo Fund, a fund closely associated with Martin Diggle, Non-Executive
Director, has purchased 9,400,000 ordinary shares of 0.1p each ('Ordinary
Shares') in the Company between 30 July 2025 and 1 August 2025 at a price of
10 pence per share. Following the purchase, Vulpes Life Science Fund and
Vulpes Testudo Fund together hold 140,284,801 ordinary shares representing
13.52% of the company.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

 

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Vulpes Testudo Fund
 2   Reason for the notification
 a)  Position/status                                              Fund closely associated with Martin Diggle, Non-Executive Director
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Scancell Holdings plc
 b)  LEI                                                          2138008RXEG856SNP666
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence each
 b)  Identification Code                                          GB00B63D3314
 c)  Nature of the transaction                                    Purchase of Ordinary Shares

 d)  Price(s) and volume(s)                                       1.   10 pence and 5,000,000

                                                                  2.   10 pence and 4,400,000
 e)  Aggregated information

     - Aggregated volume                                          9,400,000 Ordinary Shares

     - Price                                                      10 pence per Ordinary Share
 f)  Date of the transaction (s)                                  1.   30 July 2025

                                                                  2.   1 August 2025
 g)  Place of the transaction                                     London Stock Exchange, AIM

 

-ENDS-

Scancell (LSE:SCLP; www.scancell.co.uk (http://www.scancell.co.uk) ) is a
clinical stage biotechnology company developing targeted off-the-shelf active
immunotherapies, to generate safe and long-lasting tumor-specific immunity for
a cancer-free future. iSCIB1/iSCIB1+, the lead product from their DNA
Immunobody® platform has demonstrated safe, durable and clinically meaningful
benefit as a monotherapy as well as additional benefit when combined with
checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead
peptide immunotherapy from their Moditope® platform, is being investigated in
a Phase 2 study in a broad range of solid tumors. In addition, Scancell's
wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting
early-stage pipeline of high affinity GlyMab® antibodies targeting tumor
specific glycans, two of which already have been licensed and are being
developed by Genmab A/S, an international biotechnology company and global
leader in the antibody therapeutics space.

For more information please contact:

 Scancell Holdings plc                                   +44 (0) 20 3709 5700
 Phil L'Huillier, CEO
 Sath Nirmalananthan, CFO

 Panmure Liberum (Nominated Adviser and Joint Broker)    +44 (0) 20 7886 2500
 Emma Earl, Will Goode, Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                          +44 (0) 20 3705 9330

 David Wilson, Claes Spang

 Investor and media relations                            +44 (0) 20 7483 284853

 Mary-Ann Chang                                          MaryAnnChang@scancell.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSSSSULEISEEA